New dimensions in cellular immunology. Great session, some which I understood. Kids with #JIA have more cytolytic pathway missense - some leads to macrophage activation syndrome #MAS Low NK cells in Juvenile Dermatomyositis. 9T112 #ACR21 @RheumNow https://t.co/5lUkqr65UM

Abst1632 #ACR21 #ACRBest @RheumNow 25 children w/ uSAID & MEFV mutations: E148Q mutation standouts-32% heterozygous for E148Q, Asian ancestry seen in 37% kids w/ E148Q. E148Q assoc w/longer febrile episodes& less likely to have a full response to colchicine (25% vs 70%; p = 0.03) https://t.co/Rst6KHntPD

#ACR21 #Abstr1541 Any tools to help differentiate MAS vs #COVID inflammatory response? Preliminary criteria showed Sensitivity: 79.6%; Specificity: 81.3% within 6 days admission. No Triglyceride/Fibrinogen compared to 2016 ACR-EULAR & 2004 HLH @RheumNow https://t.co/c7pHaVCr5S https://t.co/6irF64qizI

• Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronav…

Telemedicine for AID patients! A fortunate pandemic outcome that PCPs shared "local" care benefit of specialists for these patients due to telemed. Abs 1062 #ACR21 @RheumNow #RheumNow https://t.co/zb0kZbzxsK

• Telemedicine Enriched Care Model to Optimize Care for Patients with Autoinflamm…

A quick recap slide on VEXAS syndrome presentation. #ACR21 @RheumNow @petercgrayson https://t.co/4x8hBEFWg2

CARRA survey in SAID pts reported no change in flare frequency w/ COVID19 but many had reduced intensity of fevers during flares. Majority of pts reported mild to moderate symptoms w/ 1/3 had lingering COVID19 symptoms. Abs 1083 #RheumNow #ACR21 @RheumNow https://t.co/qbfsqvXutt https://t.co/6u33VDIexY

• Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes …

#ACR21 #Abstr1457 Nine more well-phenotyped patients with VEXAS were presented. New info: 💠Peritubular capillaritis & cryo vasculitis 💠Most cs- & bDMARDs had limited efficacy 💠Potential therapy with plasma cell blockade & stem cell transplant @RheumNow https://t.co/iDwJAdbf4M https://t.co/X4ENz4M91u

• Clinical Heterogeneity of the VEXAS Syndrome: A Case Series - ACR Meeting Abstr…

Great Q&A re:VEXAS w/Marcela Ferrada When to suspect VEXAS? Male, MCV >100, Plt <200 Can you order genetics yourself? No. 😆 Any IMT that works? Require high dose steroid, partial response to TCZ, needs close f/u d/t possible neutropenia! How to refer to NIH? Slide!!! ⬇️⬇️ https://t.co/UvUCFbvX2r

Pulmonary Arterial Hypertension in #AOSD Rare but severe complication - life threatening French study of 13 pts - network dataset. ALL FEMALES! Age 32, mean f/u 34 mths, 5 pts (38.5%) DIED @RheumNow #ACRBest abst#1100 https://t.co/5LIzHagesP